RT Journal Article
SR Electronic
T1 Clinical characteristics of COVID-19 patients admitted to Intensive Care Unit in Panama during the first pandemic wave admissions in 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.08.22274803
DO 10.1101/2022.05.08.22274803
A1 Silvio Vega
A1 Artur Gomez Blizniak
A1 Simón Theoktisto Ballanis
A1 Gabriel Cisneros
A1 David Villalobos
A1 Ana Kathleen Armuelles
A1 Luis Moreno
A1 Francis Fusumada
A1 Johanna Gonzalez
A1 Emilio Romero
A1 Ivonne Torres-Atencio
A1 Idalina Cubilla-Batista
A1 Amador Goodridge
YR 2022
UL http://medrxiv.org/content/early/2022/05/10/2022.05.08.22274803.abstract
AB The severe acute respiratory syndrome Coronavirus 2 (SARS COV-2) caused a global pandemic of COVID-19. Most of people affected are admitted to hospital with various grades of ADRS. A small proportion of these patients requires intensive care unit management and treatment. However not all of them survive. This study aims to describe the epidemiological and clinical characteristics of patients admitted to the intensive care units in Panama main hospital in the first six months of pandemic with available information. Special focus has been oriented to blood and respiratory biomarkers to correlate with survivors and non-survivors. Our results show that patients between 56-75 years old, with hypertension, obesity, and diabetes comorbid conditions are more likely to die in intensive care units. Regarding the PaFi ratio, we observed a greater proportion of non-survivor with values less than 200. The triglycerides, urea nitrogen, creatinine and procalcitonin levels resulted significantly higher in those non survivors. During clinical management, half of patient that were administered Tocilizumab did not survived. These results support the notion that age, comorbidities as well as therapeutic management of patient in intensive care units contribute to the final outcome. We recommend reinforcing patient care strategy, especially in those patients with clinical conditions that favor fatal outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by Panama Sistema Nacional de Investigacion (SNI) from Secretaria Nacional de Ciencia Tecnologia e Innovacion (SENACYT); as well as Caja de Seguro Social.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the National Bioethics Committee Board EC-CNBI-2020-10-103.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors